Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses

• Published in: Europace (London, England) Vol. 25; no. 1; pp. 40 - 48
• Main Authors: Charitakis, Emmanouil, Dragioti, Elena, Stratinaki, Maria, Korela, Dafni, Tzeis, Stylianos, Almroth, Henrik, Liuba, Ioan, Jönsson, Anders Hassel, Charalambous, Georgios, Karlsson, Lars O, Tsartsalis, Dimitrios
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 08.02.2023
• Subjects: Anti-Arrhythmia Agents - therapeutic use; Atrial Fibrillation - diagnosis; Atrial Fibrillation - surgery; Catheter Ablation - adverse effects; Catheter Ablation - methods; Electric Countershock - adverse effects; Female; Humans; Recurrence; Review; Treatment Outcome; Electrical cardioversion; Catheter ablation • Atrial fibrillation; Umbrella review; Catheter ablation; Atrial fibrillation
• ISSN: 1099-5129; 1532-2092; 1532-2092
• DOI: 10.1093/europace/euac143

The recurrence rates after catheter ablation (CA) and direct current (DC) cardioversion remain high, although they have been established treatments of rhythm control of atrial fibrillation (AF). This umbrella review systematically appraises published meta-analyses of both observational and randomized controlled trials (RCTs) for the association of risk and protective factors for arrhythmia recurrence after CA and DC cardioversion of AF. Three bibliographic databases were searched up to June 2021. Evidence of association was rated as convincing, highly suggestive, suggestive, weak, or not significant with respect to observational studies and as high, moderate, low, or very low with respect to RCTs, according to established criteria. Thirty-one meta-analyses were included. Of the 28 associations between CA and the risk of arrhythmia recurrence, none presented convincing evidence, and only the time from diagnosis to ablation over 1 year provided highly suggestive evidence. The association between hypertension and metabolic profile provided suggestive evidence. The associations of Class IC and III antiarrhythmic drugs use with the recurrence after DC cardioversion were supported by an intermediate level of evidence. Although AF is a major health issue, few risk- and protective factors for AF recurrence have been identified. None of these factors examined were supported by convincing evidence, whereas established factors such as female gender and left atrial volume showed only weak association. An early CA strategy combined with treatment of metabolic syndrome and hypertension prior to CA may reduce the risk of arrhythmia recurrence. The use of antiarrhythmics can increase the success rate of DC cardioversion. PROSPERO registry number: CRD42021270613.